Copyright Reports & Markets. All rights reserved.

Asia-Pacific Cancer Monoclonal Antibodies Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Cancer Monoclonal Antibodies Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Naked MAbs Market Performance (Volume)
      • 2.1.2 Conjugated MAbs Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Naked MAbs Market Performance (Value)
      • 2.1.2 Conjugated MAbs Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Immune System Suppressors Market Performance (Volume)
      • 3.1.2 Kill or Inhibit Malignant Cells Market Performance (Volume)
      • 3.1.3 Deliver Chemotherapy To Cancer Cells Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 F. Hoffmann-La Roche
      • 4.1.1 F. Hoffmann-La Roche Profiles
      • 4.1.2 F. Hoffmann-La Roche Product Information
      • 4.1.3 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Business Performance
      • 4.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.2 Amgen
      • 4.2.1 Amgen Profiles
      • 4.2.2 Amgen Product Information
      • 4.2.3 Amgen Cancer Monoclonal Antibodies Business Performance
      • 4.2.4 Amgen Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.3 Bristol-Myers Squibb
      • 4.3.1 Bristol-Myers Squibb Profiles
      • 4.3.2 Bristol-Myers Squibb Product Information
      • 4.3.3 Bristol-Myers Squibb Cancer Monoclonal Antibodies Business Performance
      • 4.3.4 Bristol-Myers Squibb Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.4 Takeda Pharmaceuticals
      • 4.4.1 Takeda Pharmaceuticals Profiles
      • 4.4.2 Takeda Pharmaceuticals Product Information
      • 4.4.3 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Business Performance
      • 4.4.4 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.5 AstraZeneca
      • 4.5.1 AstraZeneca Profiles
      • 4.5.2 AstraZeneca Product Information
      • 4.5.3 AstraZeneca Cancer Monoclonal Antibodies Business Performance
      • 4.5.4 AstraZeneca Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.6 Bayer
      • 4.6.1 Bayer Profiles
      • 4.6.2 Bayer Product Information
      • 4.6.3 Bayer Cancer Monoclonal Antibodies Business Performance
      • 4.6.4 Bayer Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.7 Merck
      • 4.7.1 Merck Profiles
      • 4.7.2 Merck Product Information
      • 4.7.3 Merck Cancer Monoclonal Antibodies Business Performance
      • 4.7.4 Merck Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.8 Janssen Biotech
      • 4.8.1 Janssen Biotech Profiles
      • 4.8.2 Janssen Biotech Product Information
      • 4.8.3 Janssen Biotech Cancer Monoclonal Antibodies Business Performance
      • 4.8.4 Janssen Biotech Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.9 Novartis
      • 4.9.1 Novartis Profiles
      • 4.9.2 Novartis Product Information
      • 4.9.3 Novartis Cancer Monoclonal Antibodies Business Performance
      • 4.9.4 Novartis Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.10 OncoMed Pharmaceuticals
      • 4.10.1 OncoMed Pharmaceuticals Profiles
      • 4.10.2 OncoMed Pharmaceuticals Product Information
      • 4.10.3 OncoMed Pharmaceuticals Cancer Monoclonal Antibodies Business Performance
      • 4.10.4 OncoMed Pharmaceuticals Cancer Monoclonal Antibodies Business Development and Market Status
    • 4.11 Pfizer
    • 4.12 Eli Lilly
    • 4.13 Bristol-Myers Squibb
    • 4.14 Takeda Pharmaceuticals
    • 4.15 AstraZeneca

    5 Market Performance for Manufacturers

    • 5.1 Asia-Pacific Cancer Monoclonal Antibodies Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Asia-Pacific Cancer Monoclonal Antibodies Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Asia-Pacific Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Asia-Pacific Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 China Market Performance for Manufacturers
      • 6.1.1 China Cancer Monoclonal Antibodies Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 China Cancer Monoclonal Antibodies Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 China Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 China Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 Japan Market Performance for Manufacturers
      • 6.2.1 Japan Cancer Monoclonal Antibodies Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 Japan Cancer Monoclonal Antibodies Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 Japan Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 Japan Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 South Korea Market Performance for Manufacturers
      • 6.3.1 South Korea Cancer Monoclonal Antibodies Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 South Korea Cancer Monoclonal Antibodies Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 South Korea Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 South Korea Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Taiwan Market Performance for Manufacturers
      • 6.4.1 Taiwan Cancer Monoclonal Antibodies Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Taiwan Cancer Monoclonal Antibodies Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Taiwan Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Taiwan Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 India Market Performance for Manufacturers
      • 6.5.1 India Cancer Monoclonal Antibodies Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 India Cancer Monoclonal Antibodies Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 India Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 India Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Southeast Asia Market Performance for Manufacturers
      • 6.6.1 Southeast Asia Cancer Monoclonal Antibodies Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Southeast Asia Cancer Monoclonal Antibodies Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Southeast Asia Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Southeast Asia Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Australia Market Performance for Manufacturers
      • 6.7.1 Australia Cancer Monoclonal Antibodies Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Australia Cancer Monoclonal Antibodies Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Australia Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Australia Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Cancer Monoclonal Antibodies Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 Cancer Monoclonal Antibodies Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 Cancer Monoclonal Antibodies Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 Cancer Monoclonal Antibodies Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Asia-Pacific Cancer Monoclonal Antibodies Market Performance (Sales Point)

    • 7.1 Asia-Pacific Cancer Monoclonal Antibodies Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Asia-Pacific Cancer Monoclonal Antibodies Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Asia-Pacific Cancer Monoclonal Antibodies Price (USD/Unit) by Regions 2013-2018
    • 7.4 Asia-Pacific Cancer Monoclonal Antibodies Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Asia-Pacific Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 China Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 Japan Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 South Korea Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Taiwan Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 India Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Southeast Asia Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Australia Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Australia Cancer Monoclonal Antibodies Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Immune System Suppressors Industry
    • 11.2 Kill or Inhibit Malignant Cells Industry
    • 11.3 Deliver Chemotherapy To Cancer Cells Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Asia-Pacific Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Asia-Pacific Cancer Monoclonal Antibodies Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 China Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 Japan Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 South Korea Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Taiwan Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 India Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Southeast Asia Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Australia Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.10 Cancer Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Naked MAbs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Conjugated MAbs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Immune System Suppressors Sales and and Growth Rate 2019-2024
      • 12.4.3 Kill or Inhibit Malignant Cells Sales and and Growth Rate 2019-2024
      • 12.4.4 Deliver Chemotherapy To Cancer Cells Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Asia-Pacific Cancer Monoclonal Antibodies Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Asia-Pacific Cancer Monoclonal Antibodies Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Cancer Monoclonal Antibodies for these regions, from 2012 to 2023 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

    Asia-Pacific Cancer Monoclonal Antibodies market competition by top manufacturers/players, with Cancer Monoclonal Antibodies sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    F. Hoffmann-La Roche
    Amgen
    Bristol-Myers Squibb
    Takeda Pharmaceuticals
    AstraZeneca
    Bayer
    Merck
    Janssen Biotech
    Novartis
    OncoMed Pharmaceuticals
    Pfizer
    Eli Lilly
    Sanofi
    TG Therapeutics
    CTI BioPharma

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Naked MAbs
    Conjugated MAbs

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Cancer Monoclonal Antibodies for each application, including
    Immune System Suppressors
    Kill or Inhibit Malignant Cells
    Deliver Chemotherapy To Cancer Cells

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now